Trials / Completed
CompletedNCT00568516
Phase II Study of ASP3550 in Patients With Prostate Cancer
Phase II Study of ASP3550 - A Maintenance-dose Finding Study in Patients With Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 273 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effect of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer
Detailed description
Two doses of ASP3550 were administered to patients with prostate cancer. The primary efficacy variable was the effect of ASP3550 on the maintenance of serum testosterone suppression. In addition, the safety and pharmacokinetics of ASP3550 will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP3550 | subcutaneous administration |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2007-12-06
- Last updated
- 2014-10-29
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00568516. Inclusion in this directory is not an endorsement.